EUCTR2021-002104-12-FI进行中（未招募）1 期
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia - BEXMAB
Faron Pharmaceuticals Ltd.0 个研究点目标入组 343 人开始时间: 2021年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 343
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent.
- •2.Projected life expectancy of at least 12 weeks.
- •3.Male or female patients = 18 years of age who present with one of the following conditions:
- •a.Morphologically confirmed diagnosis of MDS based on 2016 WHO classification with indication for azacitidine treatment based on local standard medical practice with one of the following risk categories based on the rIPSS:
- •i.Very high (> 6 points)
- •ii.High (> 4.5 - = 6 points)
- •iii.Intermediate (> 3 - = 4.5 points).
- •b.Morphologically confirmed diagnosis of CMML based on 2016 WHO classification with 10-19 % marrow blasts with indication for azacitidine treatment based on local standard medical practice.
- •c.CMML and MDS patients who presents with failure to achieve response to therapy with HMA or therapy regimen including HMA. Failure is considered if the patient has not achieved CR or mCR response after 4 cycles of therapy or the disease is progressing (increasing bone marrow blast count with decreasing blood counts) during treatment with HMA.
- •d.Morphologically confirmed diagnosis of relapsed or refractory AML (except acute promyelocytic leukemia) following at least 1 line of prior therapy with indication for azacitidine treatment based on local standard medical practice.
- •e.Morphologically confirmed diagnosis of AML in patients unfit for induction therapy with indication for azacitidine-venetoclax treatment based on local standard medical practice. Specific criteria for non-eligibility for induction chemotherapy:
- •?Patient must be = 75 years of age
- •?= 18 to 74 years of age and ineligible for intensive chemotherapy meeting at least one of the criteria following:
- •Clinically significant comorbidities, as documented by at least 1 of the following:
- •oLeft ventricular ejection fraction (LVEF) = 50%.
- •oLung diffusion capacity for carbon monoxide (DLCO) = 65% of expected.
- •oForced expiratory volume in 1 second (FEV1) = 65% of expected.
- •oChronic stable angina or congestive heart failure controlled with medication.
- •oEastern Cooperative Oncology Group (ECOG) performance status 2 or 3.
- •?Other contraindication(s) to anthracycline therapy (must be documented); creatinine clearance =30 mL/min to < 45 mL/min; moderate hepatic impairment with total bilirubin > 1.5 to = 3.0 × upper limit of normal (ULN).
- •?Adverse risk genetics and/or TP53 mutation associated with poor outcome with standard chemotherapy.
- •?Antecedent MDS treated previously with standard chemotherapy and/or allogeneic transplantation.
- •4.Leukocyte count < 20x109/L (< 25 x109/L for newly diagnosed AML). Hydroxycarbamide use is permitted to meet this criterion in MDS and AML but not in CMML.
- •5.Patient must have adequate renal function as demonstrated by a calculated creatinine clearance = 30 mL/min; determined by the Cockcroft Gault formula.
- •6.Patient must have adequate liver function as demonstrated by:
- •a.ALT and aspartate transaminase (AST) = 3.0 × ULN
- •b.Bilirubin = 1.5 × ULN (unless related to Gilbert’s syndrome).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 171
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 172
排除标准
- •1.Patient has acute promyelocytic leukemia (APL).
- •2.Myeloproliferative CMML as defined by leukocyte count > 13 x109/L. Of note, the use hydroxycarbamide is not allowed to meet this criterion in patients with CMML.
- •3.ECOG >2 (except newly diagnosed AML where ECOG 3 is allowed for patients = 18 to 74 years).
- •4.Patient has known active central nervous system (CNS) involvement with myeloid malignancy (note: CSF or radiological investigations are not required without clinical suspicion). Patients with prior history of CNS involvement may be eligible if they had 2 consecutive lumbar punctures negative for CNS leukemia prior to enrollment and no clinical signs of active or progressive CNS leukemia.
- •5.Patient with human immunodeficiency virus (HIV) infection or active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
- •6.Patient has cardiovascular disability status of New York Heart Association Class >2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in palpitations, fatigue, dyspnea, or anginal pain.
- •7.Patient has a chronic respiratory disease that requires continuous oxygen use; evidence of other clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participation in this study; active or poorly controlled systemic infection requiring therapy (viral, bacterial, or fungal); or graft versus host disease requiring treatment with immunosuppressants or steroids = 10mg prednisolone or equivalent.
- •8.Allogeneic transplantation less than 6 months prior screening.
- •9.Patient has a history of other malignancies prior to study entry, with the exception of previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and have not recurred within 2 years after the last therapy prior to study treatment. Of note, patients on maintenance therapy such as tamoxifen for breast cancer or other maintenance approaches would be eligible as long as the malignancy did not recur within 2 years prior to study treatment.
- •10.Patient with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
- •11.The patient requires systemic corticosteroid (=10 mg/day prednisone or equivalent) or other immunosuppressive treatment. Topical, nasal, inhaled and ophthalmic steroids are allowed.
- •12.Use of live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit.
- •13.Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than 14 days or five half-lives (whichever is shorter) from a small molecule targeted therapy or oral anticancer chemotherapy before the first study treatment administration.
- •14.Major surgery within 4 weeks of the first dose of study treatment (procedures like insertion of a central venous access device are not considered as major surgery).
- •15.Any immunotherapy or investigational therapy within preceding 4 weeks from the first study treatment administration and during the study.
- •16.Pregnant or lactating women.
- •17.Women of child-bearing potential (WOCBP), unless they are using highly effective methods of contraception *) for at least 1 month prior to first dose of study treatment and agreement to use such a method during study participation and for an additional 12 weeks after stopping
研究者
相似试验
进行中（未招募）
不适用
A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acute Respiratory Distress Syndrome.EUCTR2008-000140-13-GBFaron Pharmaceuticals Limited
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid TumorsAdvanced or metastatic solid tumors with KRASG12C mutationsAdvanced Solid Tumors, Metastatic Solid Tumors, KRASG12CJPRN-jRCT2031220006Kitano Tina12
已完成
不适用
A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFa Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative ColitisNL-OMON40329Janssen Biologics B.V.4
进行中（未招募）
不适用
A Study to Assess the Safety and Pharmacokinetics (Serum Levels) of Golimumab in Children With Moderately to Severely Active Ulcerative ColitisEUCTR2012-004366-18-BEJanssen Biologics B.V.30
进行中（未招募）
1 期
A Study to Assess the Safety and Pharmacokinetics (Serum Levels) of Golimumab in Children With Moderately to Severely Active Ulcerative Colitislcerative Colitis in pediatric subjectsMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-004366-18-ATJanssen Biologics B.V.30